Orchard Therapeutics plc (ORTX) Income Statement Analysis

See more : QST International Corp. (8349.TWO) Income Statement Analysis – Financial Results

Complete financial analysis of Orchard Therapeutics plc (ORTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orchard Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Orchard Therapeutics plc (ORTX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.orchard-tx.com

About Orchard Therapeutics plc

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Metric	2022	2021	2020	2019	2018	2017	2016
Revenue	6.99M	483.00K	2.60M	2.51M	2.08M	0.00	0.00
Cost of Revenue	2.43M	226.00K	857.00K	805.00K	422.00K	0.00	0.00
Gross Profit	4.55M	257.00K	1.74M	1.71M	1.65M	0.00	0.00
Gross Profit Ratio	65.17%	53.21%	66.97%	67.97%	79.67%	0.00%	0.00%
Research & Development	25.55M	23.35M	93.73M	117.36M	205.32M	32.53M	16.21M
General & Administrative	44.66M	49.65M	56.89M	49.16M	0.00	5.99M	3.00M
Selling & Marketing	4.14M	5.26M	8.09M	8.06M	0.00	0.00	0.00
SG&A	10.60M	13.55M	64.99M	57.22M	31.37M	5.99M	3.00M
Other Expenses	22.66M	811.00K	3.41M	1.39M	5.51M	-1.18M	138.00K
Operating Expenses	36.15M	36.90M	158.72M	174.58M	236.69M	38.51M	19.20M
Cost & Expenses	38.58M	36.90M	159.57M	175.39M	237.11M	38.51M	19.20M
Interest Income	857.00K	63.00K	3.19M	7.36M	0.00	0.00	3.00K
Interest Expense	933.00K	683.00K	2.33M	1.54M	0.00	0.00	0.00
Depreciation & Amortization	23.51M	874.00K	8.60M	8.75M	1.20M	302.00K	6.00K
EBITDA	-8.08M	-35.54M	-148.38M	-164.12M	-235.03M	-38.21M	-19.20M
EBITDA Ratio	-115.65%	-7,358.39%	-5,717.84%	-6,531.00%	-11,321.34%	0.00%	0.00%
Operating Income	-31.59M	-36.42M	-156.98M	-172.87M	-235.03M	-38.51M	-19.20M
Operating Income Ratio	-452.22%	-7,539.34%	-6,049.25%	-6,879.15%	-11,321.34%	0.00%	0.00%
Total Other Income/Expenses	-25.95M	-3.32M	4.27M	7.21M	5.51M	-1.18M	138.00K
Income Before Tax	-9.01M	-36.22M	-152.71M	-165.66M	-229.53M	-39.69M	-19.07M
Income Before Tax Ratio	-129.00%	-7,499.79%	-5,884.78%	-6,592.20%	-11,056.12%	0.00%	0.00%
Income Tax Expense	-1.13M	125.00K	-731.00K	-2.24M	970.00K	53.00K	20.00K
Net Income	-7.88M	-36.35M	-151.98M	-163.42M	-230.50M	-39.74M	-19.09M
Net Income Ratio	-112.84%	-7,525.67%	-5,856.61%	-6,503.06%	-11,102.84%	0.00%	0.00%
EPS	-0.61	-2.93	-15.28	-17.53	-102.17	-39.37	-18.90
EPS Diluted	-0.61	-2.93	-15.28	-17.53	-102.17	-39.37	-18.90
Weighted Avg Shares Out	12.80M	12.40M	9.94M	9.32M	2.26M	1.01M	1.01M
Weighted Avg Shares Out (Dil)	12.82M	12.40M	9.94M	9.32M	2.26M	1.01M	1.01M

Got $1,000? Invest in These 2 Rare Disease Stocks

November 17, 2020fool.com

These companies are devoted to helping patients who don't have any other options.

Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit

November 9, 2020globenewswire.com

BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020...

Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting

November 5, 2020globenewswire.com

Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment

Orchard Therapeutics: An Undervalued Stock With Upcoming Catalysts

November 4, 2020seekingalpha.com

Orchard just received a positive node from CHMP for its lead drug candidate. US approval should be next.

Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020

November 2, 2020globenewswire.com

BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New Horizons in Gene Therapy' on Friday, November 13, 2020 from...